rheumatology
scleroderma

Long term results show superiority of HSCT in severe scleroderma

Long-term follow-up of patients receiving hematopoietic stem cell transplantation (HSCT) for severe scleroderma has confirmed a durable survival benefit compared to conventional treatment with cyclophosphamide. The findings, presented at the 2018 ACR/ARHP Annual Meeting in Chicago, extend the findings from the SCOT trial published earlier this year. In the SCOT trial, 75 patients with severe ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic